Navigation Links
Amgen Statement on CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer
Date:3/18/2011

the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
2. Amgen Announces Webcast of 2010 Fourth Quarter and Full Year Financial Results
3. Amgen to Acquire BioVex, a Privately Held Biotechnology Company Headquartered in Woburn, Mass
4. Amgen and Xencor Enter Option Deal to Co-Develop Xencors Novel Antibody for Autoimmune Diseases
5. Call for Applications: The Amgen Award for Science Teaching Excellence
6. Amgen Foundation Recognizes Outstanding Staff Volunteers and Contributes $55,000 to Their Favorite Local Nonprofits
7. Amgen to Provide Testimony at FDA Hearing on Biosimilars
8. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
9. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
10. Array BioPharma and Amgen Partner in Type 2 Diabetes
11. Amgen to Present at Lazard Capital Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... AZ (PRWEB) July 30, 2014 Sales ... the launch of blended sales training programs for companies ... sales training programs used by thousands of salespeople over ... blended sales training program can be customized to address ... , The blended sales training program consists ...
(Date:7/30/2014)... 2014 Vycom announces the addition of ... to meet Factory Mutual (FM) 4910 fire propagation and ... wet benches, process tools, fume hoods, furniture and cabinetry. ... to semiconductor wafers used in electronic chip manufacturing. ... solution with excellent workability and superior aesthetics. It is ...
(Date:7/30/2014)... DIEGO , July 30, 2014   Epic ... designs and develops novel diagnostics to personalize and advance ... appoint of Gregory T. Lucier as chairman ... chairman and CEO of Life Technologies (formerly Invitrogen). Mr. ... as Epic commercializes its circulating rare cell analysis platform ...
(Date:7/30/2014)... Vala Sciences was recently awarded ... Agency (EPA). This new contract was awarded for ... tests designed to assess the effect of chemical ... connections between neurons (synapses), which are critical for ... by environmental pollutants likely contributes to a variety ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Vycom Announces Flametec® Thermax PVC (FM4910 Listed) For a Variety of Clean Room Applications with Excellent Workability and Aesthetics 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3
... FREMONT, Calif., Aug. 13 WaferGen Biosystems,Inc. (OTC ... expression, genotyping, cell biology and stem cell research ... and,announced financial results for the quarter and six ... Developments and Milestones:, -- Initiation of alpha ...
... MS, EDMONTON, Aug. 12 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced financial and ... 2008. BioMS Medical, in partnership with Eli Lilly ... for the treatment of MS,undergoing pivotal trials in ...
... Calif., Aug. 12 ChromaDex,Corporation, (OTC Bulletin Board: ... research, today announced financial results for the,second quarter ... accordance with,U.S. Generally Accepted Accounting Principles (GAAP), ChromaDex ... $0.03 per share for the,three months ended June ...
Cached Biology Technology:WaferGen Announces Second Quarter 2008 Financial Results 2WaferGen Announces Second Quarter 2008 Financial Results 3WaferGen Announces Second Quarter 2008 Financial Results 4WaferGen Announces Second Quarter 2008 Financial Results 5WaferGen Announces Second Quarter 2008 Financial Results 6WaferGen Announces Second Quarter 2008 Financial Results 7WaferGen Announces Second Quarter 2008 Financial Results 8BioMS Medical Announces Second Quarter 2008 Results 2BioMS Medical Announces Second Quarter 2008 Results 3BioMS Medical Announces Second Quarter 2008 Results 4BioMS Medical Announces Second Quarter 2008 Results 5ChromaDex Announces Second Quarter 2008 Financial Results 2ChromaDex Announces Second Quarter 2008 Financial Results 3
(Date:7/30/2014)... DCToday scientists unveiled the first high-resolution map of ... entire country of Per. The new and improved ... sea change for future market-based carbon economies. ... high ecological diversity and it provides the critical ... for conservation, land use, and enforcement purposes. The ...
(Date:7/29/2014)... of Bristol,s Nutrition and Behaviour Unit (NBU) has looked ... planning meals. , The research, to be presented at ... (SSIB 2014) in Seattle, USA this week [29 July ... team was led by Professor Jeff Brunstrom, and is ... part of a Biotechnology and Biological Sciences Research Council ...
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
Breaking Biology News(10 mins):Peru's carbon quantified: Economic and conservation boon 2Peru's carbon quantified: Economic and conservation boon 3Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3
... Wake Forest University Baptist Medical Center and three ... activates the spores in anthrax, the deadly bacterial ... "A key aspect of anthrax spore biology concerns ... becomes a reproductive, disease-causing bacterium," explained Al Claiborne, ...
... Software (IOS) today,announced the release of GeneLinker(TM) ... award-winning Gene Expression and Proteomics Analysis,Software products.,"The ... and analyzing,protein biomarker data, a high priority ... have integrated the Protein Biomarker Package into ...
... deliver the hoped-for knockout punch breakthrough against the defences ... antibiotic resistance. , Techniques such as genomic sequencing and ... of new antibiotic compounds easier and more productive. But ... upper hand ?and if three billion years of bacterial ...
Cached Biology News:Scientists seek answers on what activates deadly anthrax spores 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3Learning to fight an adversary that won't stay down 2
FluoSpheres® biotin-labeled microspheres, 1.0 µm, yellow-green fluorescent (505/515) *1% solids*...
muscle actin (HUC1-1)...
FluoSpheres® biotin-labeled microspheres, 0.2 µm, yellow-green fluorescent (505/515) *1% solids*...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: